The stock's fall snapped a four-day winning streak.

Highlights:,Drive-by VCs invest in multiple startups but with minimal involvement.,They focus on quick exits rather than long-term engagement.,Their strategy contrasts with traditional venture capital ...

Highlights,New portfolio of AI-engineered proteins designed to enhance cell culture and cellular therapy.,FGF basic Heat Stable available in both RUO and GMP formats, broadening research and ...

IL-2 Heat Stable Agonist: Engineered with enhanced thermal stability and altered receptor affinity for improved biological ...

GMP Protein (E. Coli) Contract Manufacturing Market Set To Witness Significant Growth By 2025-2032: Abcam Plc, Genscript GMP Protein (E. coli) Contract manufacturing market 2025 GMP Protein (E. coli) ...

This was the stock's fourth consecutive day of gains.

The biotech group struggled as a whole in 2024, but analysts say the innovation that has always supported the biotech ...

The global Cell Therapy Technologies market, valued at US$3.89 billion in 2023, is forecasted to grow at a robust CAGR of 11.0%, ...

Bio-Techne Corporation (NASDAQ: TECH) today announced it will showcase its new ProPak™ GMP cytokines, alongside its portfolio of innovative products and solutions supporting cell and gene therapy ...

According to the latest study from BCC Research, "Cell and Gene Therapy Tools, and Reagents: Global Markets," is estimated to ...

Bio-Techne Corp. (TECH), a life sciences company, announced Tuesday that it has won a second claim of reverse engineering by Miltenyi ...

明尼阿波利斯 - Bio-Techne Corporation (NASDAQ: TECH) 再次在与Miltenyi Biotec的法律纠纷中取得胜利，科隆地区法院裁定支持这家生命科学公司。法院认定Miltenyi Biotec非法销售从Bio-Techne专有的R&D Systems品牌NKG2C/CD159c抗体反向工程而来的抗体。